TREATMENT NR547 EXAM QUESTIONS AND ANSWERS WITH COMPLETE SOLUTIONS VERIFIED

TREATMENT NR547 EXAM QUESTIONS AND ANSWERS WITH COMPLETE SOLUTIONS VERIFIED Leave the first rating Terms in this set (55) Pines SGA Sedation is a common side effect. Least risk of EPS. High risk for weight gain and metabolic abnormalities. Olanzapine (Zyprexa) "Pine" SGA FDA approved for treatment in those age 13 and older. Best tolerated antipsychotic, but high metabolic risk. Highest risk for weight gain, blood dyscrasias, QT prolongation, CVD, cerebrovascular effects, hyperglycemia, and hyperprolactinemia. Requires up to 30% dosage increase for patients who smoke. Quetiapine (Seroquel) "Pine" SGA FDA approved for treatment in those age 13 and older. Moderate metabolic risk. Low EPS risk. Risk for orthostatic hypotension, blood dyscrasias (neutropenia, leukopenia, and agranulocytosis), QT prolongation, weight gain, and renal/hepatic impairment. Asenapine (Saphris) "Pine" SGA FDA approved for age 10 and older. Available as sublingual and patch. Low metabolic risk. Clozapine (Clozaril) "Pine" SGA Approved for treatment resistant schizophrenia and chronic suicidal behavior in schizophrenia or schizoaffective disorder. Not indicated for acute presentation of schizophrenia. Low EPS risk. ANC must be 1500 when used and requires regular monitoring of WBC, granulocyte, and neutrophil counts. High metabolic risk, highest risk for weight gain, black box warning: may cause severe neutropenia. Contraindicated in liver disease/failure. Not a first choice treatment. Clozapine monitoring schedule Baseline ANC, CBC should be monitored weekly for 6 months, every 2 weeks for months 6-12, then monthly thereafter. It is the only medication approved by FDA for preventing suicide in clients with schizophrenia. 2 Dones and a Rone SGA Less sedating and cause less weight gain, but higher risk for hyperprolactinemia and EPS. Risperidone (Risperidol) "Done" SGA FDA approved for age 13 and older. Moderate metabolic risk, highest risk for hyperprolactinemia. Risk of blood dyscrasias, QT prolongation, cardiovascular and cerebrovascular effects. Dose not interact with CYP3A4 inhibitors or inducers, therefore, can be administered with medications like Amiodarone. Paliperidone (Invega) "Done" SGA FDA approved for ages 12 and older. Moderate metabolic risk Ziprasidone (Geodon) "Done" SGA FDA approved for age 10 and older. IM dosing in acute agitation associated with schizophrenia. Low metabolic risk, lowest risk for weight gain. Contraindicated with QT, recent MI, or uncompensated HF. High incidence of rash/urticaria r/t Stevens-Johnson syndrome and drug reaction with eosinophilia and systemic syndrome (DRESS).